002262.sz CH EN Enhua Pharmaceutical (Shenzhen A Share) 002262.sz CH EN
Research and development
Research and development
Important CNS drug production bases and R & D service companies in global markets
  • Scientific research and development
    Scientific research and development
  • CNS drugs
    CNS drugs
  • Cardiovascular and cerebrovascular drugs
    Cardiovascular and cerebrovascular drugs
  • Suzhou Enhua Research Institute
    Suzhou Enhua Research Institute


Enhua Technology Center is a national enterprise technology center, a provincial engineering technology research center, and a provincial engineering center. It has a national postdoctoral workstation and a national postdoctoral innovation center. The current R & D center is developing dozens of various new drugs with intellectual property rights. It undertakes more than a dozen types of national, provincial and municipal scientific research projects, complete experimental research equipment system, and has drug synthesis, formulation research, pharmacological research, drug analysis, Chinese medicine research, information retrieval and other institutions. The company always adheres to technological innovation as the driving force for the development of the company, and invests a lot of money in technological innovation, which enables the company to achieve rapid development in a short period of time. Successfully developed more than thirty products including duloxetine, risperidone, ziprasidone, etomidate fat milk, gabapentin, and zaleplon.



Accelerate the development of new medicines and follow up the development of new international medicines.


The technology center maintains close ties with well-known domestic research institutes, such as Shanghai Medical Engineering Institute, Academy of Military Medical Sciences, China Pharmaceutical University, Tianjin Academy of Pharmaceutical Sciences, and gradually expands to foreign medical research institutions to accelerate the development of new drugs. To keep up with the development of new international medicine. Various research and development centers have been set up with a number of scientific research institutes, which can independently complete the entire research process of a new drug from design synthesis, preclinical evaluation to clinical trial.


Cardio-cerebral vascular technology research and development platform


Beijing Enhua Pharmaceutical Research Center is a cardio-cerebral vascular research and development platform under Enhua Pharmaceutical. Relying on the strength of basic research on new medicines of the Cardio-cerebral-vascular Research Center of the Chinese Academy of Military Medical Sciences, it focuses on cardio-cerebral-vascular research Creative research and production development.


There are a large number of imported modern instruments and equipment here, which are fully guaranteed in terms of technological research and development of new drugs. Here you can independently complete the entire research process of a new drug from design synthesis, preclinical evaluation to clinical trial. There are research laboratories for medicinal chemistry, analytical chemistry, pharmaceutical formulation, pharmacology, toxicology, molecular biology, electronic biology, biochemistry, and biomedical information. There are a large number of doctoral supervisors, researchers, and associate researchers engaged in Research and development of new drugs. It undertakes a number of key scientific research projects such as the major national scientific research project of the 1035 project, the major scientific research project of the national 973 plan, the national 863 project, and the national small and medium enterprise innovation fund project.

Continuously develop innovative small molecule drugs and high-end generic drugs with advanced levels at home and abroad for the company


Suzhou Enhua Pharmaceutical Research Co., Ltd. (Suzhou Enhua Research Institute for short) is a wholly-owned subsidiary of Jiangsu Enhua Pharmaceutical Co., Ltd., was established on July 02, 2018, and is located in the biopharmaceutical industry at 218 Xinghu Street, Suzhou Industrial Park. Park A4-303B. The business scope covers the technical development, technical consulting, technical services, and technology transfer of chemical drugs, biomedicines, Chinese herbal medicines, medical devices, and diagnostic products.

The company focuses on central nervous diseases, including depression, schizophrenia, anesthesia and analgesia, etc., and uses international advanced drug development methods to continuously develop innovative small molecule drugs (including improved new drugs and first in class) with advanced domestic and foreign levels ) And high-end generic drugs. The company has hired senior drug R & D personnel at home and abroad to join the management team. A total of 9 departments have been set up: translational medicine department, biological evaluation department, clinical medicine department, preparation research department, chemical synthesis department, quality analysis department, CADD department, strategy Ministry of Development and Ministry of General Affairs.